Literature DB >> 27249162

Simple animal models for amyotrophic lateral sclerosis drug discovery.

Shunmoogum A Patten1, J Alex Parker2, Xiao-Yan Wen3,4, Pierre Drapeau2,4.   

Abstract

INTRODUCTION: Simple animal models have enabled great progress in uncovering the disease mechanisms of amyotrophic lateral sclerosis (ALS) and are helping in the selection of therapeutic compounds through chemical genetic approaches. AREAS COVERED: Within this article, the authors provide a concise overview of simple model organisms, C. elegans, Drosophila and zebrafish, which have been employed to study ALS and discuss their value to ALS drug discovery. In particular, the authors focus on innovative chemical screens that have established simple organisms as important models for ALS drug discovery. EXPERT OPINION: There are several advantages of using simple animal model organisms to accelerate drug discovery for ALS. It is the authors' particular belief that the amenability of simple animal models to various genetic manipulations, the availability of a wide range of transgenic strains for labelling motoneurons and other cell types, combined with live imaging and chemical screens should allow for new detailed studies elucidating early pathological processes in ALS and subsequent drug and target discovery.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; C. elegans; Drosophila; chemical genetics; drug discovery; zebrafish

Mesh:

Year:  2016        PMID: 27249162     DOI: 10.1080/17460441.2016.1196183

Source DB:  PubMed          Journal:  Expert Opin Drug Discov        ISSN: 1746-0441            Impact factor:   6.098


  7 in total

1.  Neuroleptics as therapeutic compounds stabilizing neuromuscular transmission in amyotrophic lateral sclerosis.

Authors:  Shunmoogum A Patten; Dina Aggad; Jose Martinez; Elsa Tremblay; Janet Petrillo; Gary Ab Armstrong; Alexandre La Fontaine; Claudia Maios; Meijiang Liao; Sorana Ciura; Xiao-Yan Wen; Victor Rafuse; Justin Ichida; Lorne Zinman; Jean-Pierre Julien; Edor Kabashi; Richard Robitaille; Lawrence Korngut; J Alexander Parker; Pierre Drapeau
Journal:  JCI Insight       Date:  2017-11-16

Review 2.  Zebrafish Larvae Behavior Models as a Tool for Drug Screenings and Pre-Clinical Trials: A Review.

Authors:  João Gabriel Santos Rosa; Carla Lima; Monica Lopes-Ferreira
Journal:  Int J Mol Sci       Date:  2022-06-14       Impact factor: 6.208

Review 3.  Potential new complication in drug therapy development for amyotrophic lateral sclerosis.

Authors:  Svitlana Garbuzova-Davis; Avery Thomson; Crupa Kurien; R Douglas Shytle; Paul R Sanberg
Journal:  Expert Rev Neurother       Date:  2016-07-15       Impact factor: 4.618

4.  Activation of autophagy attenuates motor deficits and extends lifespan in a C. elegans model of ALS.

Authors:  Hui Xu; Congcong Jia; Cheng Cheng; Haifeng Wu; Huaibin Cai; Weidong Le
Journal:  Free Radic Biol Med       Date:  2022-02-01       Impact factor: 7.376

Review 5.  Nearly 30 Years of Animal Models to Study Amyotrophic Lateral Sclerosis: A Historical Overview and Future Perspectives.

Authors:  Tiziana Bonifacino; Roberta Arianna Zerbo; Matilde Balbi; Carola Torazza; Giulia Frumento; Ernesto Fedele; Giambattista Bonanno; Marco Milanese
Journal:  Int J Mol Sci       Date:  2021-11-12       Impact factor: 5.923

Review 6.  Organ on a Chip: A Novel in vitro Biomimetic Strategy in Amyotrophic Lateral Sclerosis (ALS) Modeling.

Authors:  Babak Arjmand; Shayesteh Kokabi Hamidpour; Zahra Rabbani; Akram Tayanloo-Beik; Fakher Rahim; Hamid Reza Aghayan; Bagher Larijani
Journal:  Front Neurol       Date:  2022-01-17       Impact factor: 4.003

Review 7.  Caenorhabditis elegans for rare disease modeling and drug discovery: strategies and strengths.

Authors:  Peter A Kropp; Rosemary Bauer; Isabella Zafra; Carina Graham; Andy Golden
Journal:  Dis Model Mech       Date:  2021-08-09       Impact factor: 5.758

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.